News

GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has

Partners come on board GSK’s plan for Stevenage life science hub

https://pharmaphorum.com/news/partners-come-on-board-gsks-plan-for-stevenage-life-science-hub/

Why we need the human element of remote clinical trials

Digital/ News/ News/ News/ News/ Patients/ R&D

UK adds £175m funding to clinical research recovery drive

Phil Taylor access, clinical research, clinical trials, digital, digital health, UK 0 Comment

The UK government has made an additional £175 million ($212 million) in funding available for its push to

UK adds £175m funding to clinical research recovery drive

https://pharmaphorum.com/news/uk-adds-175m-funding-to-clinical-research-recovery-drive/

News/ News/ R&D

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

Phil Taylor 9 Meters Biopharma, gastrointestinal, Gattex, short bowel syndrome, Takeda, vurolenatide 0 Comment

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

https://pharmaphorum.com/news/after-coeliac-fail-9-meters-plots-phase-3-in-short-bowel-syndrome/

News/ News/ R&D

Teva poaches Vertex exec as new head of R&D

Phil Taylor R&D, senior management, Teva, Vertex Pharma 0 Comment

Teva chief executive Kare Schultz has lined up the appointment he wants to revitalise the company’s R&D operations,

Teva poaches Vertex exec as new head of R&D

https://pharmaphorum.com/news/teva-poaches-vertex-exec-as-new-head-of-rd/

News/ News/ Sales and Marketing

Bayer grabs Chinese okay for CKD therapy Kerendia

Phil Taylor Bayer, China, chronic kidney disease, Kerendia, regulatory approval 0 Comment

On the heels of approvals in the US, Europe and Japan, Bayer’s Kerendia for chronic kidney disease (CKD)

Bayer grabs Chinese okay for CKD therapy Kerendia

https://pharmaphorum.com/news/bayer-grabs-chinese-okay-for-ckd-therapy-kerendia/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ News/ Oncology/ R&D

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo 0 Comment

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/

News/ News/ News/ Oncology/ R&D

Blueprint cashes in on the past to build its future

Phil Taylor Ayvakit, Blueprint Medicines, financing, Gavreto, royalty pharma, sixth street 0 Comment

Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some

Blueprint cashes in on the past to build its future

https://pharmaphorum.com/news/blueprint-cashes-in-on-the-past-to-build-its-future/

News/ News/ R&D

Liver injuries prompt clinical hold on Sanofi BTK drug

Phil Taylor Biogen, BTK inhibitor, Merck KGaA, multiple sclerosis, myasthenia gravis, Roche, safety, Sanofi 0 Comment

One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after

Liver injuries prompt clinical hold on Sanofi BTK drug

https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login